// App-Quantinova.ai

e21164 : Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort.

Researchers

Presenter

  • Foteinos-Ioannis D. Dimtrakopoulos

Principal Investigators

  • Petros Christopoulos

  • Thomas Papastergiou

  • Eleftherios Zervas

  • Sofia Agelaki

  • Epaminondas Samantas

  • Ilias Athanasiadis

  • Sofia Baka

  • Kostas N. Syrigos

  • Athina Christopoulou

  • Evangelos Lianos

  • Nikolaos Tsoukalas

  • Eleni Isidora Perdikouri

  • Georgios Oikonomopoulos

  • Foteini Kalofonou

  • Thomas Makatsoris

  • Angelos Koutras

  • Vasileios Megalooikonomou

  • Haralabos Kalofonos

Medical Centers

  • Division of Oncology & Molecular Oncology Laboratory, Medical School, University of Patras, Patras, Greece

  • Second Department of Medical Oncology and Clinical trials Unit, Henry Dunant Hospital Center, Athens, Greece

  • Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, and Translational Lung Research Center Heidelberg, member of the German Center for Lung Research (DZL), Heidelberg, Germany

  • Computer Engineering and Informatics Department, University of Patras, Greece., Patras, Greece

  • Athens Chest Hospital, Athens, Greece

  • Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece

  • Department of Thoracic Surgery, ’Agioi Anargyroi’ General Oncology Hospital, Athens, Greece

  • On behalf of the Hellenic Society of Medical Oncology, Athens, AZ, Greece

  • Oncology Department, "Interbalkan" European Medical Center, Thessaloniki, Greece

  • Athens School of Medicine, Athens, Greece

  • Agios Andreas General Hospital, Patras, Greece

  • METAXA Special Cancer Hospital, Agios Stefanos Attiki, Greece

  • Medical Oncology Unit, NIMITS Hospital, Athens, Greece., Athens, Greece

  • Oncology Department, General Hospital of Volos, Volos, Greece

  • Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece

  • Lewisham Healthcare NHS Trust, London, United Kingdom

  • Department of InternalMedicine,University of Athens, Athens, Greece

  • Department of InternalMedicine,University of Athens, Athens, Greece

Locations

  • Greece

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Body mass index

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multicenteric

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved